Amoy Diagnostics Co Ltd - Company Profile

Powered by

All the sales intelligence you need on Amoy Diagnostics Co Ltd in one solution.

$195 $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Amoy Diagnostics Co Ltd fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Amoy Diagnostics Co Ltd.

Back to companies

Amoy Diagnostics Co Ltd: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Amoy Diagnostics Co Ltd (AmoyDx) is a medical equipment company that develops, manufactures and distributes diagnostics for oncology precision medicine. The company offers products such as hrd focus panel, hrd complete panel, master panel, brca pro panel, handle classic ngs panel, essential ngs panel, handle hrr ngs panel, pan lung cancer pcr panel, handle oncopro ngs panel, handle oncopro compact ngs panel, myeloid blood cancer panel, report automation software (aras pcr), comprehensive panel, handle melanoma ngs panel, multi-gene mutations detection kit, met mutation detection kit, and her2 mutation detection kit, among others. It markets its products under Super-ARMS and AmoyDx brand names. The company operates China and Singapore. AmoyDx is headquartered in Xiamen, Fujian, China.

 Gain a 360-degree view of Amoy Diagnostics Co Ltd and make more informed decisions for your business Gain a 360-degree view of Amoy Diagnostics Co Ltd and make more informed decisions for your business Learn more
Headquarters China
Address No.39, Dingshan Road, Haicang District, Xiamen, Fujian, 361027
Website www.amoydx.com
No of Employees 1,175
Industry Medical Equipment
Ticker Symbol & Exchange 300685 (SHE)
Revenue (2024) $166.7M 8% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 41.7% (2024 vs 2023)
Market Cap* $993.0M
Net Profit Margin (2024) XYZ 31.2% (2024 vs 2023)
   
* As of and is in US$
View Amoy Diagnostics Co Ltd financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Amoy Diagnostics Co Ltd premium industry data and analytics

11+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

10+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Amoy Diagnostics Co Ltd’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
HRD Focus Panel Super-ARMS
HRD Complete Panel AmoyDx
Master Panel
XYZ
XYZ
XYZ
Understand Amoy Diagnostics Co Ltd portfolio and identify potential areas for collaboration Understand Amoy Diagnostics Co Ltd portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2026 Regulatory Approval In August, the company secured approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the AmoyDx Pan Lung Cancer PCR Panel as a companion diagnostic (CDx) for trastuzumab deruxtecan in Japan for patients with unresectable advanced or recurrent non-small cell lung cancer with HER2 mutations.
2026 Contracts/Agreements In June, the company entered into an agreement to sell its 20% stake to Sinopharm Group (Beijing) Science and Technology Innovation Research Institute Co., Ltd.
2025 Regulatory Approval In December, the company's AmoyDx received approval from the National Medical Products Administration in China for the companion diagnostic for MET exon 14 skipping mutations for Tabrecta (Capmatinib Hydrochloride Tablets).
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters Amoy Diagnostics Co Ltd Guangzhou Wondfo Biotech Co Ltd Shanghai Kehua Bio-engineering Co Ltd Beijing Strong Biotechnologies Inc Dirui Industrial Co Ltd
Headquarters China China China China China
City Xiamen Guangzhou Shanghai Beijing Changchun
State/Province Fujian Guangdong Shanghai Beijing Jilin
No. of Employees 1,175 2,443 1,870 998 1,569
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Li-Mou Zheng Chairman Executive Board 2015 73
Frank Ron Zheng Director; Senior Vice President Executive Board 2021 36
Luo Jiemin Director; General Manager Executive Board 2021 43
Chen Ying Secretary; Chief Financial Officer Senior Management 2021 56
Yang Shuang Deputy General Manager Senior Management 2025 39
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Amoy Diagnostics Co Ltd key executives to enhance your sales strategy Gain insight into Amoy Diagnostics Co Ltd key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?